APRE
APRE
NASDAQ · Biotechnology

Aprea Therapeutics Inc

$0.75
-0.01 (-1.18%)
As of Sep 28, 10:46 PM ET ·
Financial Highlights (FY 2026)
Revenue
545.5K
Net Income
-24,052,037
Gross Margin
—
Profit Margin
-4,409.1%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 49.5% 49.5% 49.5%
Operating Margin -4,631.1% 10.4% 11.1% 11.3%
Profit Margin -4,409.1% 8.1% 10.4% 10.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 545.5K 1.10M 1.13M 1.14M
Gross Profit — 542.9K 561.3K 563.8K
Operating Income -25,261,446 114.1K 125.9K 128.7K
Net Income -24,052,037 89.2K 117.7K 115.4K
Gross Margin — 49.5% 49.5% 49.5%
Operating Margin -4,631.1% 10.4% 11.1% 11.3%
Profit Margin -4,409.1% 8.1% 10.4% 10.1%
Rev Growth — +5.3% -7.0% -3.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 493.4K 556.8K 520.5K
Total Equity — 2.95M 2.97M 2.85M
D/E Ratio — 0.17 0.19 0.18
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -25,221,623 177.4K 182.1K 193.3K
Free Cash Flow — 70.9K 72.7K 77.2K